<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331499</url>
  </required_header>
  <id_info>
    <org_study_id>SAL-SP-10-001</org_study_id>
    <nct_id>NCT01331499</nct_id>
  </id_info>
  <brief_title>Salient Aquamantys Spine Trial</brief_title>
  <official_title>A Post-Market, Prospective, Multicenter, Randomized Trial Comparing the Use of Standard of Care Blood Sparing Techniques With and Without the Aquamantys System to Facilitate Hemostasis in Subjects Undergoing Multi-level Spinal Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salient Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salient Surgical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare standard of care hemostasis techniques with and&#xD;
      without the use of Aquamantys in reducing peri-operative blood loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to assess the effectiveness of Aquamantys in reducing&#xD;
      peri-operative blood loss compared with standard electrocautery&#xD;
&#xD;
      Secondary objectives include :&#xD;
&#xD;
        -  Rate and volume of transfusions&#xD;
&#xD;
        -  Evaluating the reduction in hemoglobin and hematocrit values post- operatively&#xD;
&#xD;
        -  LOS costs, and operative time&#xD;
&#xD;
        -  Gathering operator feedback on qualitative criteria, including ease of use and surgical&#xD;
           visualization between the two treatment groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to Medtronic acquisition&#xD;
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual Peri-operative Blood Loss</measure>
    <time_frame>Up to 72 hours post-operatively</time_frame>
    <description>Actual blood loss (ABL) will be calculated using a study specified formula using laboratory data from up to 72 hours post-surgery. ABL will be compared between treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and volume of transfusions</measure>
    <time_frame>Up to 72 hours post-operatively</time_frame>
    <description>The frequency and volume of transfusions will be measured between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in hemoglobin and hematocrit values post-operatively</measure>
    <time_frame>Upto 72 hours post-operatively</time_frame>
    <description>The reduction in hemoglobin and hematocrit values will be evaluated between the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay costs and operativ time</measure>
    <time_frame>Up to 21 days post-operatively</time_frame>
    <description>Total length of staycosts and operative time will be compared between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Bipolar Sealer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care blood sparing techniques with bipolar sealer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care blood sparing techniques without the use of bipolar sealer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar Sealer (Aquamantys)</intervention_name>
    <description>Standard of care blood sparing techniques along with the use of bipolar sealer</description>
    <arm_group_label>Bipolar Sealer</arm_group_label>
    <other_name>Aquamantys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care blood sparing techniques without the useof bipolar sealer</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be candidate for three level (or greater) fusion surgery from T1 to S1 utilizing a&#xD;
             direct posterior approach&#xD;
&#xD;
          2. Male or female 18 to 70 years of age (inclusive)&#xD;
&#xD;
          3. Must sign the IRB approved Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Undergoing spinal fusion for &lt; 3 lumbar levels, or using an approach other than direct&#xD;
             posterior&#xD;
&#xD;
          2. Undergoing an interbody fusion&#xD;
&#xD;
          3. Planned use of hypotensive anaesthesia&#xD;
&#xD;
          4. Pregnant or lactating&#xD;
&#xD;
          5. Morbid obesity, defined as Body Mass Index (BMI) greater than 40&#xD;
&#xD;
          6. Previously diagnosed coagulopathy or bleeding diasthesis&#xD;
&#xD;
          7. Currently, or within the previous 7 days prior to surgery, taking any medications that&#xD;
             would produce bleeding diathesis including, but not limited to NSAIDs, aspirin,&#xD;
             clopidogrel (Plavix), ticlopidine, or valproic acid&#xD;
&#xD;
          8. History of significant cardiac disorders that would necessitate special fluid&#xD;
             management protocols&#xD;
&#xD;
          9. Serious trauma other than that confined to the spine&#xD;
&#xD;
         10. History of acute myocardial infarction and/or acute angina within the past year prior&#xD;
             to enrollment&#xD;
&#xD;
         11. PT/INR &gt;1.3 in the 14 days prior to surgery&#xD;
&#xD;
         12. PTT &gt; 40 in the 14 days prior to surgery&#xD;
&#xD;
         13. Platelet count &lt;100K in the 14 days prior to surgery&#xD;
&#xD;
         14. Based on clinical history, physical exam and subject presentation, subject has or is&#xD;
             suspected to have a history of alcohol and/or drug abuse that would preclude subject&#xD;
             from providing adequate consent and/or complying with study requirements&#xD;
&#xD;
         15. Prisoner or transient&#xD;
&#xD;
         16. Enrolled in another drug or device investigational study (currently or within past 30&#xD;
             days)&#xD;
&#xD;
         17. Unable or unwilling to sign the Informed Consent Form or comply with protocol&#xD;
             specified procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Fischgrund, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood loss</keyword>
  <keyword>transfusions</keyword>
  <keyword>instrumented spinal fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 25, 2014</submitted>
    <returned>July 22, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

